FINWIRES · TerminalLIVE
FINWIRES

Pfizer Says Elrexfio Significantly Improves Progression-Free Survival in People With Blood Cancer

By

Pfizer (PFE) said Wednesday a phase 3 trial assessing Elrexfio to treat adults with multiple myeloma showed a significant improvement in the primary endpoint of progression-free survival compared with daratumumab plus pomalidomide and dexamethasone.

The candidate drug's safety and tolerability was in line with its known safety profile, the company said, adding that most people treated with the drug remained progression-free.

The company said the study is ongoing to evaluate overall survival, which is a key secondary endpoint, that was not yet mature at the time of the interim analysis.

Price: $26.43, Change: $-0.05, Percent Change: -0.21%

Related Articles

Wire

Brown-Forman, Pernod Ricard End Talks on Potential Combination

Brown-Forman (BF.A) and Pernod Ricard ended discussions over a potential business combination after failing to reach mutually agreeable terms."We intend to create long-term value for all stakeholders by focusing on our strategic and operational priorities," Brown-Forman said Tuesday in a statement. "This includes unlocking future growth by expanding our geographic footprint, continuing to build brands that resonate with consumers, and enhancing operational efficiency."In late March, the companies confirmed they were in talks, noting "there could be no assurance that any such agreement would be reached."Brown-Forman shares fell 2.9% in after-hours trading.

$BF.A$BF.B
Wire

Update: Visa Fiscal Q2 Adjusted Earnings, Revenue Rise

(Updates with share repurchase and dividend information in the last two paragraphs.)Visa (V) reported fiscal Q2 adjusted earnings late Tuesday of $3.31 per diluted share, up from $2.76 a year earlier.Analysts polled by FactSet expected $3.10.Revenue for the three months ended March 31 was $11.23 billion, up from $9.59 billion a year earlier.Analysts polled by FactSet expected $10.75 billion.In April, the company's board authorized a new $20 billion multi-year share repurchase program, it said.Visa also maintained its quarterly dividend at $0.67 per share, payable June 1 to holders on record as of May 12.

$V
Wire

BXP Q1 FFO Falls, Revenue Rises; Shares Drop After Hours

BXP Inc (BXP) reported Q1 funds from operations late Tuesday of $1.59 per diluted share, down from $1.64 a year earlier.Analysts surveyed by FactSet expected $1.58.Revenue in the three months ended March 31 rose to $872.1 million from $865.2 million a year earlier.Analysts polled by FactSet expected $843.1 million.The company expects FFO of $1.69 to $1.71 a share in Q2 and $6.90 to $7.04 a share in the full year, compared with the prior forecast of $6.88 to $7.04.Analysts surveyed by FactSet expect $1.72 in Q2 and $6.95 in the full year.BXP shares fell 4.6% in after-hours trading.

$BXP